Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
